Kymera Therapeutics (KYMR) Aktievy
Kymera Therapeutics, Inc, ett biofarmaceutiskt företag i klinisk fas, fokuserar på att upptäcka och utveckla småmolekylära läkemedel som selektivt bryter ned sjukdomsframkallande proteiner genom att utnyttja kroppens eget naturliga proteinnedbrytningssystem. Mer information
| Snöflinga Score | |
|---|---|
| Värdering | 2/6 |
| Framtida tillväxt | 2/6 |
| Tidigare resultat | 0/6 |
| Finansiell hälsa | 6/6 |
| Utdelningar | 0/6 |
Belöningar
Riskanalys
KYMR Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Kymera Therapeutics, Inc. Konkurrenter
Prishistorik och prestanda
| Historiska aktiekurser | |
|---|---|
| Aktuell aktiekurs | US$78.89 |
| 52 veckors högsta | US$103.00 |
| 52 veckors lägsta | US$28.06 |
| Beta | 2.06 |
| 1 månads förändring | -11.13% |
| 3 månaders förändring | -9.74% |
| 1 års förändring | 167.51% |
| 3 års förändring | 168.15% |
| 5 års förändring | 64.05% |
| Förändring sedan börsintroduktionen | 137.19% |
Senaste nyheter och uppdateringar
Recent updates
Uppdatering av berättelse • May 06
KYMR: Future Type 2 Disease Milestones Will Support Oral Degrader Leadership
Analysts have made a small downward adjustment to Kymera Therapeutics' modeled fair value, trimming the target by about $0.29 as they factor in more cautious revenue growth and profit margin assumptions while still highlighting the potential of the oral STAT6 degrader platform and broader degrader pipeline. Analyst Commentary Recent Street research on Kymera Therapeutics centers on how much value to put on the oral STAT6 degrader KT-621 and the broader degrader pipeline, with several firms revising price targets while maintaining generally constructive views on the long term opportunity.Uppdatering av berättelse • Apr 21
KYMR: Future Type 2 Disease Milestones Will Support Oral Degrader Upside
Kymera Therapeutics' blended analyst price target now centers around $119, as analysts fine-tune their models following a mix of upward and downward revisions that reflect updated views on the potential of its STAT6 degrader programs and broader degrader pipeline. Analyst Commentary Recent Street research around Kymera Therapeutics clusters around constructive views on its STAT6 degrader and broader degrader pipeline, but with some differing opinions on how much of that potential is already reflected in current valuation.Seeking Alpha • Apr 13
Kymera: 'Strong Buy' On Continued Success With KT-621 In Th2-Driven Disorders
Summary Kymera Therapeutics remains a "Strong Buy", driven by positive phase 1b data for KT-621 in atopic dermatitis and pipeline expansion. KT-621 achieved a mean 63% EASI reduction and 40% pruritus NRS reduction, supporting advancement into phase 2b BROADEN2 [AD] and BREADTH [asthma] trials. Both AD and asthma programs received FDA Fast Track Designation, with mid-2027 [BROADEN2] and late-2027 [BREADTH] data readouts as key milestones. KYMR holds $1.6B in cash, providing runway into 2029 to support clinical milestones and potential expansion into multiple Th2-driven inflammatory indications. Read the full article on Seeking AlphaUppdatering av berättelse • Apr 07
KYMR: Future Type 2 Disease Data Will Drive Oral Degrader Upside
Analysts' blended price target for Kymera Therapeutics has shifted modestly within a range of about $100 to $140 as they weigh updated Q4 data, progress across the degrader pipeline, and the potential of the STAT6 program as an oral alternative to existing biologics in type 2 diseases. Analyst Commentary Recent research notes cluster around a constructive stance on Kymera Therapeutics, with most firms adjusting price targets within a relatively tight US$100 to US$140 band as they reassess Q4 updates, the degrader pipeline, and the potential of the STAT6 program in type 2 diseases.Uppdatering av berättelse • Mar 23
KYMR: Future Type 2 Disease Milestones Will Drive Oral Degrader Upside
The analyst fair value estimate for Kymera Therapeutics has edged down slightly from about $119.71 to $119.14. This reflects updated assumptions on discount rate, profitability, and future P/E following recent Street research that includes both higher and lower price targets tied to progress in the STAT6 degrader pipeline and broader type 2 disease opportunities.Uppdatering av berättelse • Mar 07
KYMR: Future Type 2 Disease Data Will Support Upside Potential
Narrative Update The analyst fair value estimate for Kymera Therapeutics has increased by about $3 to $119.71 as analysts factor in recent price target revisions that highlight confidence in the type 2 disease opportunity and Kymera's oral protein degrader pipeline. Analyst Commentary Recent research updates show a generally constructive tone on Kymera Therapeutics, with most price targets clustered in a relatively tight range and anchored to expectations around the type 2 disease opportunity and the oral protein degrader pipeline.Uppdatering av berättelse • Feb 20
KYMR: Future Atopic Dermatitis And Asthma Data Will Support Upside Potential
Analysts have slightly raised their price targets on Kymera Therapeutics, reflecting updated assumptions around discount rates, revenue growth, profit margins, and a very high future P/E that incorporate both the recent Overweight initiation at Barclays and the downgrade to Peer Perform at Wolfe Research. Analyst Commentary Recent research views on Kymera Therapeutics are mixed, with one firm initiating with a positive stance and another firm moving to a more neutral rating.Uppdatering av berättelse • Feb 05
KYMR: Future Atopic Dermatitis And Asthma Data Will Drive Upside Potential
Narrative Update Analysts have slightly reduced their fair value estimate for Kymera Therapeutics to about US$116.71 from roughly US$116.76, reflecting modest tweaks to the discount rate, long term revenue growth assumptions, and a very high future P/E multiple following mixed recent Street views that include both an Overweight initiation and a downgrade to Peer Perform. Analyst Commentary Recent Street views on Kymera Therapeutics have been mixed, with one firm assuming coverage with an Overweight rating and another moving to a more neutral stance at Peer Perform.Uppdatering av berättelse • Jan 22
KYMR: Upcoming Atopic Dermatitis Data Will Drive Future Upside Potential
Narrative update on Kymera Therapeutics The updated analyst price target for Kymera Therapeutics moves to about $70 to $73, reflecting mixed sentiment across recent research. Some analysts cite increased confidence in KT-621 and upcoming atopic dermatitis data as key supports for their higher targets, while one firm shifted to a more neutral rating.Uppdatering av berättelse • Jan 08
KYMR: Upcoming Atopic Dermatitis Data And Fast Track Status Will Drive Upside
Analysts have nudged their price expectations for Kymera Therapeutics higher, with our fair value estimate moving from US$114 to about US$116.76 as they factor in higher Street targets supported by growing optimism around KT-621 and upcoming clinical readouts. Analyst Commentary Recent Street research around Kymera Therapeutics shows a mix of optimism and caution, with most attention focused on KT-621 and its upcoming atopic dermatitis data, while one firm has stepped back from a previously more constructive stance.Uppdatering av berättelse • Dec 15
KYMR: Upcoming Atopic Dermatitis Milestones Will Drive Significant Long Term Upside Potential
Kymera Therapeutics' fair value estimate has been raised from $77.59 to $114.00 as analysts lift price targets into the $60 to $80 range. They cite growing conviction in KT-621 ahead of key Phase 1b atopic dermatitis data and its potential for significant long term sales.Uppdatering av berättelse • Nov 30
KYMR: Upcoming Atopic Dermatitis Data Will Unlock Major Upside Potential
Kymera Therapeutics' analyst price target has increased from approximately $74.55 to $77.59. This reflects analysts' growing optimism around upcoming KT-621 clinical milestones and anticipated efficacy data in atopic dermatitis.Uppdatering av berättelse • Nov 16
KYMR: Upcoming Atopic Dermatitis Data Will Drive Confidence And Momentum
Analysts have raised their price target on Kymera Therapeutics from approximately $69 to $75. This reflects increased optimism around KT-621 data and strengthened near-term revenue growth projections.Uppdatering av berättelse • Nov 01
KYMR: Advancing Clinical Milestones Will Drive Meaningful Upside in Immunology Indications
Kymera Therapeutics’ analyst price target has increased from $65 to approximately $69, as analysts cite strengthening conviction in the company's KT-621 program and positive upcoming clinical milestones as key drivers for the higher outlook. Analyst Commentary Recent assessments by street analysts show growing optimism surrounding Kymera Therapeutics, particularly regarding the advancement and potential of its KT-621 program.Uppdatering av berättelse • Oct 18
Advancing STAT6 And TYK2 Clinical Programs Will Open New Therapeutic Markets
The analyst price target for Kymera Therapeutics has increased modestly from $64.33 to $65.00, as analysts cite strengthened conviction in the KT-621 program and the anticipated impact of upcoming Phase 1b and Phase 2 clinical data as key drivers of valuation. Analyst Commentary Recent research highlights both optimism and caution regarding Kymera Therapeutics as the company's KT-621 program advances through clinical stages.Uppdatering av berättelse • Oct 04
Advancing STAT6 And TYK2 Clinical Programs Will Open New Therapeutic Markets
Analysts have revised Kymera Therapeutics' fair value target down to approximately $64 from $72. This adjustment is based on updated models that reflect mixed expectations for growth as well as newly anticipated milestones for KT-621 clinical progress.Analysartikel • Aug 14
Earnings Update: Kymera Therapeutics, Inc. (NASDAQ:KYMR) Just Reported And Analysts Are Boosting Their Estimates
As you might know, Kymera Therapeutics, Inc. ( NASDAQ:KYMR ) last week released its latest second-quarter, and things...
Ny berättelse • Mar 21
Advancing STAT6 And TYK2 Clinical Programs Will Open New Therapeutic Markets
Advancing clinical programs and strategic partnerships could increase market share and positively impact future revenue and earnings.Seeking Alpha • Feb 19
Kymera Therapeutics: Plenty Of Potential, But A Long Way From The Finish Line
Summary Today, I circle back to Kymera Therapeutics, which is focused on developing small-molecule therapeutics that degrade disease-causing proteins. The company's pipeline has several 'shots on goal', targeting potentially very large indications and is partnered with drug giant Sanofi for its lead candidate. Kymera has $900 million in cash and no long-term debt, funding operations into mid-2027. An updated analysis around Kymera Therapeutics follows in the paragraphs below. Read the full article on Seeking AlphaSeeking Alpha • Dec 07
Kymera: Protein Degradation Could Drive Dupixent-Like Value
Summary Kymera Therapeutics' KT-474, partnered with Sanofi, is in Phase 2 trials for Hidradenitis Suppurativa and Atopic Dermatitis, with completion of studies expected mid-2026. KT-621, a STAT6 degrader for immuno-inflammatory disorders, shows promise with Phase 1 data expected in the first half of 2025. The company has $911 million in cash, sufficient to fund operations into mid-2027, covering key milestones and pipeline developments. KT-295 is another candidate in its pipeline, being developed as a TYK2 protein degrader to target inflammatory disorders like IBD. Read the full article on Seeking AlphaSeeking Alpha • Oct 06
Kymera's Protein Degradation Technology: A Promising Bet For Long-Term Biotech Investors
Summary Kymera Therapeutics' innovative TPD technology degrades disease-causing proteins, with promising candidates like KT-474 and KT-621 targeting large TAMs in immunology and oncology. The company's approach leverages the body’s proteasome system to degrade harmful proteins. This could lead to safer and less invasive treatments. Kymera's cash runway of approximately 4.9 years is expected to support the advancement of its pipeline until 2027. I believe the company's strong cash runway and strategic partnership with Sanofi bolster its financial stability and expedite KT-474's development and market adoption. Despite clinical trial risks, KYMR's promising IP and large market potential make it a compelling long-term investment, rated a "Buy" for informed biotech investors. Read the full article on Seeking AlphaSeeking Alpha • Mar 21
Kymera Therapeutics: Advancing Into Phase 2 With Partner Sanofi - I Still Have Faith
Summary Kymera Therapeutics' shares have dropped from $81 to $39 since my note back in 2021, but have risen >130% in the past 6m. The company's technology targets the ubiquitin proteasome system to degrade disease-causing proteins. Kymera's lead candidate, KT-474, is being developed to treat autoimmune conditions and has shown promising results in Phase 1 studies. Partner Sanofi has opted to take KT-474 into Phase 2 studies, paying $55m to do so. Kymera has struggled since reaching post-IPO highs of >$80, but preclinical and clinical validation of several programs offers fresh hope of long-term recovery. Read the full article on Seeking AlphaAktieägarnas avkastning
| KYMR | US Biotechs | US Marknad | |
|---|---|---|---|
| 7D | -4.0% | 1.2% | 1.0% |
| 1Y | 167.5% | 34.9% | 28.7% |
Avkastning vs industri: KYMR översteg US Biotechs branschen som gav 34.9 % under det senaste året.
Avkastning vs Marknaden: KYMR översteg US marknaden som gav 28.7 % under det senaste året.
Prisvolatilitet
| KYMR volatility | |
|---|---|
| KYMR Average Weekly Movement | 5.6% |
| Biotechs Industry Average Movement | 11.0% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.1% |
Stabil aktiekurs: KYMR har inte haft någon betydande prisvolatilitet under de senaste 3 månaderna jämfört med marknaden för US.
Volatilitet över tid: KYMR s veckovolatilitet ( 6% ) har varit stabil under det senaste året.
Om företaget
| Grundad | Anställda | VD OCH KONCERNCHEF | Webbplats |
|---|---|---|---|
| 2015 | 253 | Nello Mainolfi | www.kymeratx.com |
Kymera Therapeutics, Inc. är ett biofarmaceutiskt företag i klinisk fas som fokuserar på att upptäcka och utveckla småmolekylära läkemedel som selektivt bryter ned sjukdomsframkallande proteiner genom att utnyttja kroppens eget naturliga proteinnedbrytningssystem. Företaget utvecklar KT-621, en oral STAT6-degraderare i kliniska fas 2b-studier för måttlig till svår atopisk dermatit, astma, KOL, EoE, CRSwNP, CSU, PN, BP m.fl. och KT-579, en oral IRF5-degraderare i fas 1-studier för autoimmuna sjukdomar som systemisk lupus erythematosus, reumatoid artrit, inflammatorisk tarmsjukdom, SSc, DM m.fl; KT-485/SAR447971, IRAK4-programmet, som befinner sig i klinisk fas II-studie för behandling av immunologiska inflammationssjukdomar, inklusive hidradenitis suppurativa och atopisk dermatit; och cyklinberoende kinas 2 (CDK2) med bred onkologisk behandlingspotential, inklusive bröstcancer och andra solida tumörer. Bolaget har en strategisk allians med Sanofi S.A. för utveckling av läkemedelskandidater inriktade på IRAK4 utanför onkologi- och immunonkologiområdena.
Kymera Therapeutics, Inc. Sammanfattning av grunderna
| KYMR grundläggande statistik | |
|---|---|
| Börsvärde | US$6.63b |
| Vinst(TTM) | -US$315.00m |
| Intäkter(TTM) | US$51.48m |
126.1x
P/S-förhållande-20.6x
P/E-förhållandeÄr KYMR övervärderat?
Se Verkligt värde och värderingsanalysResultat & intäkter
| KYMR resultaträkning (TTM) | |
|---|---|
| Intäkter | US$51.48m |
| Kostnad för intäkter | US$334.48m |
| Bruttovinst | -US$283.00m |
| Övriga kostnader | US$32.01m |
| Intäkter | -US$315.00m |
Senast redovisade vinst
Mar 31, 2026
Nästa vinstdatum
n/a
| Vinst per aktie (EPS) | -3.83 |
| Bruttomarginal | -549.77% |
| Nettovinstmarginal | -611.94% |
| Skuld/egenkapitalförhållande | 0% |
Hur har KYMR utvecklats på lång sikt?
Se historisk utveckling och jämförelseFöretagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/05/22 05:50 |
| Aktiekurs vid dagens slut | 2026/05/22 00:00 |
| Intäkter | 2026/03/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Kymera Therapeutics, Inc. bevakas av 38 analytiker. 22 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Etzer Darout | Barclays |
| Eliana Merle | Barclays |
| Zhiqiang Shu | Berenberg |